ArticleAdvanced materials (Deerfield Beach, Fla.)2018
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy.
Article in Advanced materials (Deerfield Beach, Fla.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Engineered cell-biomimetic nanosystems for anti-inflammatory therapy: Targeting, neutralization and immunomodulation.Acta pharmaceutica Sinica. B · 2026Review
- Nitric Oxide-Releasing Catheters with Phenol-Amine Catalytic Coatings for Improved Anti-Inflammatory Performance.Advanced healthcare materials · 2025Article
- GENRISE-induced superior extracellular vesicles for scalable therapeutic cargo delivery.Science advances · 2025Article
- A strategy to prepare robust enzyme@covalent organic framework microcapsules: a new platform for biosensing.Bioactive materials · 2025Article
- AntagomiR-192-5p-engineered exosomes encapsulated in MXene-modified GelMA hydrogel facilitated epithelization of burn wounds by targeting OLFM4.Bioactive materials · 2025Article
- Review of research progress in immobilization and chemical modification of microbial enzymes and their application.Microbial cell factories · 2025Review
- Extracellular Vesicles-in-Hydrogel (EViH) targeting pathophysiology for tissue repair.Bioactive materials · 2025Review
- Engineered and Mimicked Extracellular Nanovesicles for Therapeutic Delivery.Nanomaterials (Basel, Switzerland) · 2024Review
- Prokaryotic microvesicles Ortholog of eukaryotic extracellular vesicles in biomedical fields.Cell communication and signaling : CCS · 2024Review
- Extracellular vesicle-based biovectors in chronic wound healing: Biogenesis and delivery approaches.Molecular therapy. Nucleic acids · 2023Review
- Extracellular vesicle-matrix interactions.Nature reviews. Materials · 2023Article
- Review
- Emerging Roles of Mesenchymal Stem/Stromal-Cell-Derived Extracellular Vesicles in Cancer Therapy.Pharmaceutics · 2023Review
- Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy.Tissue engineering and regenerative medicine · 2023Review
- Endogenous Lipid Carriers-Bench-to-Bedside Roadblocks in Production and Drug Loading of Exosomes.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Production and Utility of Extracellular Vesicles with 3D Culture Methods.Pharmaceutics · 2023Review
- Native and engineered exosomes for inflammatory disease.Nano research · 2023Review
- Bioengineering Extracellular Vesicles for the Treatment of Cardiovascular Diseases.Advanced biology · 2022Review
- Emerging micro-nanotechnologies for extracellular vesicles in immuno-oncology: from target specific isolations to immunomodulation.Lab on a chip · 2022Review
- Extracellular vesicles from colorectal cancer cells promote metastasis via the NOD1 signalling pathway.Journal of extracellular vesicles · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Extracellular vesicles (EVs) have recently gained significant attention as important mediators of intercellular communication, potential drug carriers, and disease biomarkers. These natural cell-derived nanoparticles are postulated to be biocompatible, stable under physiological conditions, and to show reduced immunogenicity as compared to other synthetic nanoparticles. Although initial clinical trials are ongoing, the use of EVs for therapeutic applications may be limited due to undesired off-target activity and potential "dilution effects" upon systemic administration which may affect their ability to reach their target tissues. To fully exploit their therapeutic potential, EVs are embedded into implantable biomaterials designed to achieve local delivery of therapeutics taking advantage of enzyme prodrug therapy (EPT). In this first application of EVs for an EPT approach, EVs are used as smart carriers for stabilizing enzymes in a hydrogel for local controlled conversion of benign prodrugs to active antiinflammatory compounds. It is shown that the natural EVs' antiinflammatory potential is comparable or superior to synthetic carriers, in particular upon repeated long-term incubations and in different macrophage models of inflammation. Moreover, density-dependent color scanning electron microscopy imaging of EVs in a hydrogel is presented herein, an impactful tool for further understanding EVs in biological settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.